Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

FlavenGlaven Nov. 17 at 12:13 AM

$AUTL the institutional movement in this stock is even crazier than I originally thought. Encourage everyone to look through the recent buy and sell filings. Looks like MAK capital took the entire 26 mil shares from Wellington. Hopefully he can be the activist we need to get a return.

1 · Reply

cravs Nov. 15 at 8:30 PM

$AUTL The biotech name I’m watching into December. December catalysts (high impact): ✅ Phase 2 obexelimab data – ALL efficacy update expected Q4 2025 / early Jan ✅ Big Pharma partnership rumors intensifying (AZN, NVS, GSK in the mix) ✅ Short interest = 18% – squeeze potential if data lands ✅️ EV/Real +294% (upside) Not financial advice. DYOR.

2 · Reply

gandolf63 Nov. 15 at 4:40 PM

$AUTL

0 · Reply

wussel Nov. 15 at 7:37 AM

$AUTL Upcoming Events Nov 18, 2025 at 7:30 AM EST Jefferies Global Healthcare Conference https://www.autolus.com/investor-relations-media/events/

1 · Reply

gandolf63 Nov. 14 at 10:27 PM

$AUTL

2 · Reply

FlavenGlaven Nov. 14 at 7:46 PM

$AUTL Very similar chart setup to 5/15

0 · Reply

JcoalX Nov. 14 at 7:20 PM

$AUTL Renaissance has held this bad boy for 26 quarters now owning close to 5million shares. Surely us retail investors can hold for another 3 quarters to see this company become profitable!

0 · Reply

Waves87 Nov. 14 at 6:14 PM

$CDTX Jumping into $AUTL for the next adventure.

1 · Reply

GeniusLoci Nov. 14 at 5:39 PM

$AUTL Schroeder and Renaissance each reported multimillion share buys in Q3

0 · Reply

FlavenGlaven Nov. 14 at 4:46 PM

$AUTL interesting institutional shakeup with the Q3 report filing done. Not a sell off, but more w change in hands. Blackrock and Wellington selling, Renaissance and Jane St buying, etc etc

1 · Reply

Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline

Nov 13, 2025, 4:05 PM EST - 3 days ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 3:11 PM EST - 4 days ago

Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:00 AM EST - 4 days ago

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 3, 2025, 9:05 AM EST - 13 days ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 30, 2025, 7:00 AM EDT - 17 days ago

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 27, 2025, 7:00 AM EDT - 20 days ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 20, 2025, 7:00 AM EDT - 27 days ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Oct 15, 2025, 4:05 PM EDT - 4 weeks ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 8:05 AM EDT - 2 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 5:26 PM EDT - 3 months ago

Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable

Aug 12, 2025, 4:37 PM EDT - 3 months ago

Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 4 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 4 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jun 12, 2025, 2:00 AM EDT - 5 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 6, 2025, 11:09 AM EDT - 5 months ago

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

May 29, 2025, 4:05 PM EDT - 6 months ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 6 months ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 20, 2025, 5:47 AM EDT - 6 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC CAPR CLPT EDIT NTLA VANI VERV

May 14, 2025, 9:30 AM EDT - 6 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 11, 2025, 4:22 AM EDT - 6 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 7 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 7 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 8 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 11:55 AM EDT - 8 months ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 8 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 9 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 4, 2025, 10:21 AM EST - 9 months ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Jan 17, 2025, 7:00 AM EST - 10 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 12:16 AM EST - 1 year ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 12, 2024, 2:57 PM EST - 1 year ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Sep 6, 2024, 2:12 PM EDT - 1 year ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Aug 10, 2024, 12:05 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

May 31, 2024, 8:00 AM EDT - 1 year ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 12:55 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

May 17, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 1:02 PM EDT - 1 year ago

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 15, 2024, 5:23 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

FlavenGlaven Nov. 17 at 12:13 AM

1 · Reply

cravs Nov. 15 at 8:30 PM

2 · Reply

gandolf63 Nov. 15 at 4:40 PM

$AUTL

0 · Reply

wussel Nov. 15 at 7:37 AM

$AUTL Upcoming Events Nov 18, 2025 at 7:30 AM EST Jefferies Global Healthcare Conference https://www.autolus.com/investor-relations-media/events/

1 · Reply

gandolf63 Nov. 14 at 10:27 PM

$AUTL

2 · Reply

FlavenGlaven Nov. 14 at 7:46 PM

$AUTL Very similar chart setup to 5/15

0 · Reply

JcoalX Nov. 14 at 7:20 PM

$AUTL Renaissance has held this bad boy for 26 quarters now owning close to 5million shares. Surely us retail investors can hold for another 3 quarters to see this company become profitable!

0 · Reply

Waves87 Nov. 14 at 6:14 PM

$CDTX Jumping into $AUTL for the next adventure.

1 · Reply

GeniusLoci Nov. 14 at 5:39 PM

$AUTL Schroeder and Renaissance each reported multimillion share buys in Q3

0 · Reply

FlavenGlaven Nov. 14 at 4:46 PM

$AUTL interesting institutional shakeup with the Q3 report filing done. Not a sell off, but more w change in hands. Blackrock and Wellington selling, Renaissance and Jane St buying, etc etc

1 · Reply

Michael_garic Nov. 14 at 4:43 PM

$AUTL Let's keep some perspective. This company has an FDA approved treatment for people that previously were looking at a death sentence. They will soon have a treatment for untreatable immune diseases. I believe that is their focus right now. Getting a cure out there for otherwise terminal patients. They have a new CFO, he will focus on costs and accelerating revenue. The only ones selling today are short sellers and impatient investors. Warren Buffet was famous for saying buy a company you believe in, hold their stock for ten years, and don't look at the price every day, or something like that.

0 · Reply

PokerMunkee Nov. 14 at 4:42 PM

$AUTL Just bought a starter position of 1k at 1.38. My apologies if this crashes now.

1 · Reply

FlavenGlaven Nov. 14 at 4:36 PM

$AUTL nice looking double bottom and forming a strong base.

0 · Reply

Deivittt Nov. 14 at 4:26 PM

$CDTX The second one. $AUTL Podium. Interesting. https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/

0 · Reply

Deivittt Nov. 14 at 4:24 PM

$AUTL The second one. Podium. Interesting. https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/

0 · Reply

TricksterT Nov. 14 at 4:07 PM

Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline (NASDAQ:AUTL) | Seeking Alpha $AUTL https://seekingalpha.com/article/4843847-autolus-therapeutics-trading-at-cash-is-not-justified-with-this-pipeline

1 · Reply

MedHS55 Nov. 14 at 3:38 PM

$AUTL Nice article on Seeking Alpha

1 · Reply

chelfen Nov. 14 at 2:41 PM

$AUTL if you mean Biontech… no, their focus is on BNT327 and not so much on CAR-T any more. Maybe BMY…? and for sure not for 3B..

1 · Reply

yoter Nov. 14 at 12:47 PM

$AUTL buyout most likely candidate is Biontax. It has already a significant share of AUTL, its market value is $25B . And it needs additional products to bolster its future revenue streams. The b/o price could amount to $3B, by next year. (roughly ten times current valuation). I foresee a bidding war on autl acquisition. I have increased my holdings in the past couple of days, to buy cheap during the downturn.

2 · Reply

gandolf63 Nov. 14 at 11:12 AM

$AUTL the pipeline will save us

1 · Reply

Omnivest Nov. 14 at 10:06 AM

$AUTL 👇👇GREAT NEWS!👇👇

1 · Reply

JcoalX Nov. 14 at 2:57 AM

$AUTL

0 · Reply

Market Cap	364.61M
Revenue (ttm)	10.12M
Net Income (ttm)	-220.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,180.43%
Debt to Equity Ratio	0.00

Volume	3,034,200
Avg Vol	3,599,564
Day's Range	N/A - N/A
Shares Out	266.14M
Stochastic %K	46%
Beta	1.84
Analysts	Strong Sell
Price Target	$9.59